319 related articles for article (PubMed ID: 26637787)
1. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
2. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
3. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
[TBL] [Abstract][Full Text] [Related]
4. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
Gough SM; Chung YJ; Aplan PD
PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
[TBL] [Abstract][Full Text] [Related]
5. Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product.
Byrne M; Bennett RL; Cheng X; May WS
Neoplasia; 2014 Aug; 16(8):627-33. PubMed ID: 25220590
[TBL] [Abstract][Full Text] [Related]
6. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
7. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.
Lin YW; Slape C; Zhang Z; Aplan PD
Blood; 2005 Jul; 106(1):287-95. PubMed ID: 15755899
[TBL] [Abstract][Full Text] [Related]
8. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
[TBL] [Abstract][Full Text] [Related]
9. Brief report: Loss of p15Ink4b accelerates development of myeloid neoplasms in Nup98-HoxD13 transgenic mice.
Humeniuk R; Koller R; Bies J; Aplan P; Wolff L
Stem Cells; 2014 May; 32(5):1361-6. PubMed ID: 24449168
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic
Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
Xu H; Menendez S; Schlegelberger B; Bae N; Aplan PD; Göhring G; Deblasio TR; Nimer SD
Blood; 2012 Oct; 120(15):3089-97. PubMed ID: 22927245
[TBL] [Abstract][Full Text] [Related]
12. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
13. TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
Monlish DA; Greenberg ZJ; Bhatt ST; Leonard KM; Romine MP; Dong Q; Bendesky L; Duncavage EJ; Magee JA; Schuettpelz LG
Exp Hematol; 2020 Aug; 88():42-55. PubMed ID: 32652111
[TBL] [Abstract][Full Text] [Related]
14. Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.
Wang H; Sun J; Zhang B; Zhao D; Tong H; Wu H; Li X; Luo Y; Dong D; Yao Y; McDonald T; Stein AS; Al Malki MM; Pichiorri F; Carlesso N; Kuo YH; Marcucci G; Li L; Jin J
Clin Transl Med; 2021 Oct; 11(10):e610. PubMed ID: 34709739
[TBL] [Abstract][Full Text] [Related]
15. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation.
Slape C; Hartung H; Lin YW; Bies J; Wolff L; Aplan PD
Cancer Res; 2007 Jun; 67(11):5148-55. PubMed ID: 17545593
[TBL] [Abstract][Full Text] [Related]
16. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
[TBL] [Abstract][Full Text] [Related]
17. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.
Chung YJ; Robert C; Gough SM; Rassool FV; Aplan PD
Leuk Res; 2014 Jan; 38(1):95-102. PubMed ID: 23958061
[TBL] [Abstract][Full Text] [Related]
19. Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome.
Chung YJ; Khawaja G; Wolcott KM; Aplan PD
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30346380
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
